FDA Updates Import Alert Including Red List of E-Cigarettes

Regulations by 2FIRSTS.ai

Jun.05.2024

FDA Updates Import Alert Including Red List of E-Cigarettes

The FDA has updated import alerts, including a "red list" for e-cigarette products, giving Customs authority for seizure.

According to a statement from the US Food and Drug Administration (FDA), the FDA has updated its import alert, which includes a "red list" of products that will authorize US Customs and Border Protection to detain potential aerosol products without the need for physical inspection.

A new alert allows for the addition of 13 new e-cigarette manufacturers and distributors (10 of which are from China). If the new tobacco products do not comply with the requirements of the Federal Food, Drug, and Cosmetic Act to obtain the necessary marketing authorization, U.S. Customs and Border Protection will have the authority to seize their goods.

The 13 new companies and their associated products added in 2024 are as follows:

References:

[1] Import Alert 98-06

Also Read:

[1] FDA Seeks Civil Penalties for 10 Retailers Selling Unauthorized ELFBAR

[2] FDA Warns of More Addictive 6-Methyl Nicotine, Patents Owned by Several Chinese Companies

[3] FDA Introduces Searchable Tobacco Product Database with Enhanced Features

[4] FDA Releases Additional Regulatory Science Policy Memoranda on PMTA

[5] Altria Submits PMTA for NJOY ACE 2.0 to FDA

[6] Senate Urges FDA Enforcement on Unauthorized E-Cigarette Sales Review

#North America #United States #Open system e-cigarettes #Disposable e-cigarettes #Regulation #Customs #FDA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours

The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.

Dec.22 by 2FIRSTS.ai

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.

Nov.14 by 2FIRSTS.ai

Global Tobacco Companies’ Latest Earnings Review: Nicotine Pouch Business Shows Broad Strength, Emerging as a Key Growth Driver

Multiple global tobacco and next-generation nicotine companies reported solid Q3 performance, with the nicotine-pouch category showing broad-based strength across seven firms. Growth was reflected in higher shipment volumes, expanded market coverage, and new product launches. Several companies also reported rising revenue contributions from pouches and continued investment in this fast-growing segment, underscoring its position as a key driver of future growth.

Nov.14

Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%

Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.